ESLA - Kewajiban jangka dawa perusahaan Estrella Immunopharma Inc

Estrella Immunopharma (ESLA) faces serious threats due to a lack of profitability and fierce competition in the leukemia treatment sector, rendering the asset volatile. This chart on GURU.Markets demonstrates the 0.00 metric, which correlates with rising research costs as the clinic network expands. Meanwhile, production capacities in California rely on third-party bio-factories to minimize technical failures.

This indicator measures the aggregate volume of liabilities with a maturity of more than one year, reflecting the issuer's long-term financial stability and capital development strategy. For Estrella Immunopharma (ESLA), the borrowing balance is critical during the automation of drug synthesis, as AI-design costs require investment; however, the company's long-term debt trend allows for an assessment of the risk of dependence on external financing when conducting costly clinical trials.